At its meeting of October 31, 2022, the Board of Directors of Hybrigenics SA (Euronext Paris – FR0004153930 – ALHYG) approved the parent company financial statements for 1
er
half of the 2022 financial year (ended June 30, 2022), summarized below. The figures mentioned in this press release are taken from the half-year accounts, in accordance with French accounting standards. The 2022 half-year report is available on the company’s website, www.hybrigenics.com.
Half-year results
Financial statements data in €m – French standards | S1 2021 |
S1 2022 |
Turnover | 0.0 |
0.0 |
Operating result | -0.1 |
-0.2 |
Net profit | -0.1 |
-0.2 |
The company Hybrigenics SA did not record any turnover in the 1
er
semester 2022.
As a reminder, Hybrigenics now has a holding activity, essentially focused on the management of its subsidiaries and the maintenance of the patent portfolio linked to historical research activities. Hybrigenics SA and its subsidiaries form the DMS Biotech division, which supports the development strategy of DMS Group in the field of biotechnology. As of June 30, 2022, DMS Group held 43.14% of the capital of Hybrigenics SA.
The operating loss increased from one semester to the next, to -235 K€. Operating expenses, mainly fees related to the company’s listing on Euronext Growth and the maintenance of the patent portfolio until 2021, are now also made up of the salaries of the team in charge of financial management, administrative and human resources of the subsidiaries.
Balance sheet position as of June 30, 2022
Hybrigenics SA’s balance sheet total fell from €10.6 million as of June 30, 2021 to €13.0 million as of June 30, 2022.
On the asset side, fixed assets fell from €5.8 million as of June 30, 2021 to €9.0 million as a result of the entry into the capital of Inoviem Scientific (see below). Current assets amount to €3.8 million, including €3.7 million in receivables from DMS Group.
On the liabilities side, corporate equity amounts to €10.0 million compared to €6.6 million as of June 30, 2021. Hybrigenics SA presents in its balance sheet a financial debt of €1.3 million relating to the investment transaction in Inoviem Scientific, and a debt with related parties (DMS Group) of €1.9 million. Trade payables remained stable at €0.2 million.
Other information
At its meeting of October 31, 2022, the Hybrigenics SA Board of Directors approved the change of the company’s registered office, which will be transferred to Strasbourg.
Hybrigenics SA and DMS Group signed a memorandum of understanding on October 19, 2022 to organize the sale of all the shares held by DMS Group to the capital of Hybrigenics, so that each of the companies can focus on its core business. This operation will notably allow Hybrigenics to have the opportunity to open up its capital to one or more major players in the pharmaceutical industry.
About Hybrigenics
Hybrigenics is a listed biopharmaceutical company (ALHYG) in Paris on the Euronext Growth market of Euronext, eligible for the PEA-PME.
Hybrigenics and its subsidiaries make up the DMS Biotech division, which supports the development strategy of DMS Group (Euronext Paris – FR0012202497 – DGM) in the field of biotechnology, oncology, regenerative medicine and anti-aging medicine. It specializes in the development of innovative technical solutions using adipose tissue cells, and particularly stem cells.
More information at www.hybrigenics.com.
Hybrigenics is listed on the Euronext Growth market of Euronext Paris – ISIN: FR0004153930 – Ticker: ALHYG – Eligible PEA-PME
Hybrigenics
Leone ATAYI
Executive Director
[email protected]
09 71 04 32 63
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
l5qdZsdqk2yVnZyeZZ1uZmOVmmhkyJaWZWeWx2RwZpmUnZ5kmZxmaZaWZnBolWhu
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Press release on accounts, results
Full and original press release in PDF format:
https://www.actusnews.com/news/77038-hybrigenics-cp-rs2022-02112022-vdef.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com